Next Generation Sequencing For Industry Outlook by Size, Share
Meticulous Research®—a
leading global market research company, published a research report titled, ‘Next-Generation
Sequencing (NGS) Market: Industry Outlook by Offering (Sample Preparation [DNA
Extraction, Library Preparation, Automation], Systems, Bioinformatics,
Sequencing Services) Application (Clinical, Research) End User - Global
Forecast to 2031’
According to this
latest publication from Meticulous Research®, the next-generation
sequencing (NGS) market is projected to reach $42.7
billion by 2031, at a CAGR of 15.7% during the forecast period. The growth of the NGS market is driven by
the rising cancer prevalence & the increasing application of NGS in cancer
treatment and research, partnerships between NGS service providers &
pharmaceutical companies, technological advancements in NGS, the growing demand
for optimized & streamlined NGS workflows, the declining costs of genome
sequencing, technological advancements in sequencing procedures, technological
advancements in NGS informatics solutions, increasing pharmaceutical R&D
expenditures, the surge in genome mapping programs, and improvements in
regulatory & reimbursement scenarios for NGS-based diagnostic tests.
However, the high costs of NGS systems and consumables, the high costs of
automation workstations, data confidentiality concerns, the availability of
alternative technologies, the low chances of identifying positive, actionable
mutations for precision medicine, and ethical & legal issues related to
NGS-based diagnosis restrain the growth of this market.
Key Players
The key players
operating in the next-generation sequencing (NGS) market are Illumina, Inc.
(U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd.
(Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent
Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.),
Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), MGI Tech
Co., Ltd. (China), Tecan Group Ltd. (Switzerland), Beijing Genomics Institute
(BGI) (China), Eppendorf AG (Germany), Hamilton Company (U.S.), Hudson Robotics
(U.S.), LGC Limited (U.K.), Fabric Genomics, Inc. (U.S.), DNASTAR, Inc. (U.S.),
Eurofins Scientific SE (Luxembourg), Novogene Co. Ltd. (China), and Quest
Diagnostics Incorporated (U.S.).
Leading Drivers
Fueling NGS Market Expansion:
A convergence of
powerful factors is driving rapid expansion in the NGS market. Chief among
these is the rising prevalence of cancer, which has led to an urgent need for
enhanced diagnostics and personalized treatment solutions. NGS is now
increasingly adopted in clinical oncology, not only for identifying actionable
genetic mutations but also for monitoring disease recurrence through molecular
residual disease (MRD) assays—exemplified by new whole-genome sequencing
solutions for ctDNA detection recently launched by Illumina Inc. in partnership
with Janssen Research & Development. Pharmaceutical companies and NGS
service providers have formed strategic partnerships, further speeding adoption
of genomic testing in therapeutic development and patient care.
Advancements in
sequencing technology and informatics have dramatically improved the speed and
accuracy of genome analysis, while declining costs make NGS accessible to a
broader range of hospitals, laboratories, and research institutions. The trend
toward more optimized and automated workflows—spanning sample preparation, data
analysis, and bioinformatics solutions—has reduced turnaround times and
increased the efficiency of large-scale projects.
Technological
Trends Shaping the Future:
The future of NGS
hinges on several key technological innovations. Comprehensive sequencing
platforms, such as sequencing by synthesis and nanopore sequencing, now deliver
highly accurate genomic data, minimizing sequence-specific errors and
empowering researchers to explore complex regions of the genome. Bioinformatics
advancements have enabled secure, efficient data management, allowing seamless
sharing and multi-team access to large genomic datasets.
Clinical applications
of NGS are expanding, particularly in precision medicine, rare disease
diagnosis, and early cancer detection. NGS supports personalized treatment
strategies by identifying genetic variability and tailoring interventions to
individual patient profiles. Informatics solutions help streamline workflows by
automating analysis, monitoring instrument run quality, and transforming raw
sequencing data into actionable clinical information.
Furthermore,
automation in library preparation, sequencing protocols, and data analysis
continues to enhance reliability, reproducibility, and scalability, which are
critical for high-throughput research and clinical operations. As large-scale
genome mapping programs and collaborative research initiatives proliferate, the
adoption of NGS technologies is set to accelerate even further.
Regions Leading
Market Growth:
North America
currently dominates the NGS market, accounting for 48.7% of the global share in
2024. The region’s growth is underpinned by strong R&D investment,
proactive government initiatives in genomics, higher awareness of NGS testing,
and a favorable reimbursement environment. The U.S.—with its concentration of
major market players, cutting-edge research, and robust pharmaceutical
sector—remains a powerhouse for NGS adoption and innovation.
However, the
Asia-Pacific region stands out for its explosive growth potential, forecasted
to experience the highest expansion rate at 16.9% CAGR through 2031. China and
India, in particular, are investing heavily in healthcare infrastructure,
genome sequencing programs, and drug discovery, creating significant
opportunities for NGS vendors. Government support for biotechnology, affordable
skilled workforce, and increasing incidence of genetic diseases and cancer are
accelerating market expansion across Asia-Pacific. These trends are gradually
shifting the global landscape, with new research hubs and collaborative
projects gaining momentum.
Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5957
Key Questions
Answered in the Report:
- Which are the high-growth market segments
in terms of offering, application, end user, and region/country?
- What was the historical market size for
next-generation sequencing (NGS) products across the globe?
- What are the market forecasts and
estimates for 2024–2031?
- What are the major drivers, restraints,
opportunities, and challenges in the global next-generation sequencing
(NGS) market?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment